Lee’s Pharma licenses RegeneRx thymosin-based products
The terms of the transaction include aggregate potential milestone payments of up to $3.6m and royalties ranging from low double digit to high single digit royalties on commercial
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The Hamburg facility will be equipped with technology from Agilent including multiple RapidFire High-throughput Mass Spectrometry Systems and 6460 Triple Quadrupole instrumentation. Agilent vice president biological systems division